Lactate is always the end product of glycolysis by Matthew J. Rogatzki et al.
PERSPECTIVE ARTICLE
published: 27 February 2015
doi: 10.3389/fnins.2015.00022
Lactate is always the end product of glycolysis
Matthew J. Rogatzki1, Brian S. Ferguson2, Matthew L. Goodwin3 and L. Bruce Gladden4*
1 Department of Health and Human Performance, University of Wisconsin-Platteville, Platteville, WI, USA
2 Department of Biomedical Sciences, University of Missouri, Columbia, MO, USA
3 Department of Orthopaedics, and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA






Avital Schurr, University of
Louisville, USA
George A. Brooks, University of
California, USA
*Correspondence:
L. Bruce Gladden, School of
Kinesiology, Auburn University, 301
Wire Road, Auburn, AL 36849, USA
e-mail: gladdlb@auburn.edu
Through much of the history of metabolism, lactate (La−) has been considered merely
a dead-end waste product during periods of dysoxia. Congruently, the end product
of glycolysis has been viewed dichotomously: pyruvate in the presence of adequate
oxygenation, La− in the absence of adequate oxygenation. In contrast, given the
near-equilibrium nature of the lactate dehydrogenase (LDH) reaction and that LDH has
a much higher activity than the putative regulatory enzymes of the glycolytic and
oxidative pathways, we contend that La− is always the end product of glycolysis.
Cellular La− accumulation, as opposed to flux, is dependent on (1) the rate of
glycolysis, (2) oxidative enzyme activity, (3) cellular O2 level, and (4) the net rate of
La− transport into (influx) or out of (efflux) the cell. For intracellular metabolism, we
reintroduce the Cytosol-to-Mitochondria Lactate Shuttle. Our proposition, analogous to the
phosphocreatine shuttle, purports that pyruvate, NAD+, NADH, and La− are held uniformly
near equilibrium throughout the cell cytosol due to the high activity of LDH. La− is always
the end product of glycolysis and represents the primary diffusing species capable of
spatially linking glycolysis to oxidative phosphorylation.
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INTRODUCTION
In the nineteenth century, ≈80 years after the discovery of lactate
(La−) by Scheele (Kompanje et al., 2007), Louis Pasteur noticed
that facultative yeast cells grew more under aerobic than anaer-
obic conditions, yet the consumption of sugar was decreased
and fermentation to alcohol was less under aerobic conditions
(Pasteur, 1861). Previously, Pasteur (1858) had recognized that
some types of yeast fermented sugar to La− under anaerobic,
but not aerobic conditions. This phenomenon (for both alco-
hol and La− fermentation) has been called the Pasteur Effect
(Barnett and Entian, 2005). A parallel phenomenon was discov-
ered in skeletal muscle and whole animals. For skeletal muscle
Fletcher and Hopkins (1907) reported that La− accrued in anaer-
obic frog muscles at rest. During stimulation, La− concentration
([La−]) increased rapidly in anaerobic amphibian muscle, but
disappeared when these fatigued muscles were allowed to recover
in an oxygen (O2) rich environment. Subsequently, Meyerhof
demonstrated conclusively that glycogen was the precursor of La−
in isolated muscles, and the full glycolytic pathway was eluci-
dated by the early 1940s (Meyerhof, 1942; Brooks and Gladden,
2003). The traditional dogma was built upon this framework and
other research on hypoxia: Pyruvate is the end product of glycol-
ysis under aerobic conditions and La− is the end product when
O2 is insufficient. Schurr (2006) discussed this dogma from the
viewpoint of brain metabolism.
It is widely accepted that intracellular PO2 values of ≈0.5
Torr or less result in O2-limited oxidative phosphorylation, a
condition termed dysoxia (Connett et al., 1990), with ensuing
La− production and accumulation. However, Stainsby andWelch
(1966) reported La− efflux from an ostensibly well-oxygenated
contracting muscle. Subsequently, Jöbsis and Stainsby (1968)
observed La− production and release from a contracting canine
skeletal muscle while the NAD+/NADH redox couple was becom-
ing more oxidized, an indication of adequate O2 supply. Using a
different approach, myoglobin cryomicrospectroscopy, to deter-
mine PO2 in dog gracilis muscle contracting at progressively
faster rates, Connett et al. (1986) found increasing La− efflux
without evidence of dysoxia; the lowest PO2 values were generally
on the order of 2 Torr. Richardson et al. (1998) used proton mag-
netic resonance spectroscopy (MRS) to determine myoglobin sat-
uration (and thereby intracellular PO2) in humans during graded
exercise. In parallel experiments with the same type of exercise,
La− efflux was determined via arteriovenous concentration dif-
ferences and blood flow. They found La− efflux in the presence of
intracellular PO2 levels (∼3 Torr) that should not limit oxidative
phosphorylation. Véga et al. (1998) also reported that isolated,
stimulated nerve tissue releases lactate during aerobic conditions.
These findings, along with other abundant circumstantial
evidence indicate that net La− production and efflux from
cells can occur under aerobic conditions (Gladden, 2004a,b).
In fact, Brooks (2000) proposed that “lactate was produced all
the time in fully oxygenated cells and tissues.” Schurr (2006)
discussed this proposition in detail, proposing that “glycoly-
sis always proceeds to its final step, the LDH reaction and the
formation of lactate” in brain tissue but most likely in many
other tissues as well. Subsequently, Schurr and Payne (2007) and
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Schurr and Gozal (2012) provided supportive experimental evi-
dence for this postulate in hippocampal brain slices. Here, we
embrace this concept, proposing that even in the absence of net
La− accumulation, and in the presence of plentiful O2, La− is the
natural end product of glycolysis. Importantly, we use basic bio-
chemical principles to undergird this concept and re-introduce
the Cytosol-to-Mitochondria Lactate Shuttle.
THE LDH REACTION IS A NEAR EQUILIBRIUM REACTION
La− is formed in the following reaction that is catalyzed by the
enzyme lactate dehydrogenase (LDH):
Pyruvate− + NADH + H+ ↔ Lactate− + NAD+
The equilibrium constant is strongly in favor of La− (1.62 ×
1011 M−1) (Lambeth and Kushmerick, 2002), and LDH activity
is high relative to the putative regulatory enzymes in the gly-
colytic pathway in skeletal muscle (Connett and Sahlin, 2011),
liver, kidney, cardiac muscle, spleen, and fat (Shonk and Boxer,
1964), brain (Iwangoff et al., 1980;Morland et al., 2007), and both
malignant and benignmammary tumors (Larner and Rutherford,
1978; Balinsky et al., 1984). Importantly, LDH activity is also high
in comparison to the putative regulatory enzymes of pyruvate
oxidation; see Spriet et al. (2000) for skeletal muscle, Morland
et al. (2007) for brain, and Marie and Shinjo (2011) for brain
cancer. While measures of tissue La− to pyruvate ratios are
scarce, some example values are ≈7:1 for liver (Liaw et al., 1985),
≈10–13:1 for resting skeletal muscle (Sahlin et al., 1976; Liaw
et al., 1985), and values as high as 159:1 in skeletal muscle imme-
diately following exhaustive dynamic exercise (Sahlin et al., 1976).
Reference values for the La− to pyruvate ratio in the brain,
using microdialysis probes, average 23:1 (Reinstrup et al., 2000;
Sahuquillo et al., 2014). Typically, the ratio rises following trau-
matic brain injury, even in the absence of ischemia or low tissue
PO2 {≥ 25(Sahuquillo et al., 2014); ≥40 (Vespa et al., 2005)}.
Despite standardization of techniques, microdialysis values do
not necessarily reflect real tissue concentrations (Sahuquillo et al.,
2014). Nevertheless, these La− to pyruvate microdialysis values
for human brain are not far afield from values (≈13:1) obtained
on rat brain homogenates (Ponten et al., 1973). Overall, the high
[La−] relative to [pyruvate] even with adequate O2 supply, rein-
forces the role of LDH activity in determining La− appearance.
The high LDH activity and La−-leaning equilibrium constant of
the LDH reaction are key elements in the proposition that La− is
the major end product of glycolysis under essentially all metabolic
conditions. Simply put, any time glycolysis is operative, regard-
less of local oxygen tension, La− is being formed in most types of
tissues. However, the amount of La− produced and actually accu-
mulated (i.e., an increased [La−]) can be altered by factors such as
O2 tension, metabolic rate, available mitochondrial activity, and
other factors.
FATES OF PYRUVATE
Potential fates of pyruvate are listed below. We propose that none
of these processes occurs at a rate that matches the initial conver-
sion of pyruvate to La−, thus ensuring that La− is always the end
product of glycolysis.
1. Efflux from the cell primarily via monocarboxylate
transporters (MCTs). However, La− is always present in
a higher concentration than pyruvate and will depart cells at a
faster rate than will pyruvate.
2. Conversion to alanine via the near equilibrium alanine amino-
transferase reaction which has an equilibrium constant of
about 1 (Tiidus et al., 2012), so alanine concentration should
approximate pyruvate concentration and the conversion of
pyruvate to alanine should not detract from the conversion of
pyruvate to La−.
3. Gluconeogenic/Glyconeogenic reactions. In gluconeogenic tis-
sues, pyruvate can be converted to oxaloacetate in a reaction
catalyzed by pyruvate carboxylase (Pascoe and Gladden, 1996).
In skeletal muscle glyconeogenesis, pyruvate can be converted
to malate with catalysis by malic enzyme (Pascoe and Gladden,
1996) or more likely to phosphoenolpyruvate via reversal
of the pyruvate kinase reaction (Donovan and Pagliassotti,
2000). These reactions represent “reversal” of glycolysis and
they begin with La−, the natural end product of glycoly-
sis. In the brain, glycogen is most abundant in astrocytes
and sparse to negligible in neurons (Cataldo and Broadwell,
1986). Although pyruvate carboxylase is expressed in cul-
tured astroglial cells, oligodendrocytes, microglial cells, and
ependymocytes (Murin et al., 2009), we are unaware of any
information on the ability of any of these cells to synthesize
glycogen from La−.
4. Transport across the mitochondrial inner membrane with
subsequent conversion to Acetyl-CoA via the pyruvate dehy-
drogenase (PDH) reaction followed by entry into the tricar-
boxylic acid cycle and oxidation. Pyruvate crosses the inner
mitochondrial membrane via simple diffusion and facilitated
diffusion; the transporters are an MCT (Hashimoto et al.,
2006) and the mitochondrial pyruvate carrier (Divakaruni
and Murphy, 2012). For ongoing oxidation of pyruvate,
NADH shuttling into the mitochondrial matrix by the malate-
aspartate and glycerol phosphate shuttles is equally important
as pyruvate transport.
The constant presence of La− and its accumulation during peri-
ods of glycolytic stimulation is evidence that the LDH reaction
predominates over these alternative fates of pyruvate.
Figure 1 illustrates a model of intracellular metabolism which
we call the “Cytosol-to-Mitochondria Lactate Shuttle”; its origin
can be traced to a review of La− metabolism by Stainsby and
Brooks (1990). Because of the high LDH activity and an equi-
librium constant far in the direction of La−, La− is always the
predominant result of glycolysis. However, formation of La− is
not synonymous with La− accumulation and increased [La−].
Mitochondria constitute a sink for pyruvate and under condi-
tions of slow glycolytic activity with ample O2, oxidation in
most cells is sufficient to closely match production by glycoly-
sis; transmembrane La− flux will vary between slow release and
slow uptake with release being the more typical condition. In a
manner analogous to creatine kinase and the Phosphocreatine
Shuttle, LDH holds pyruvate and La− in equilibrium through-
out the cell cytosol. In this scenario, La− is the primary species
that travels to the neighborhood of the mitochondrial reticulum,
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FIGURE 1 | Illustration of the essential elements of the re-introduced
Cytosol-to-Mitochondria Lactate Shuttle. A high activity of cytosolic LDH
is considered to guarantee La− formation in the cytosol under virtually all
conditions but especially during periods of increased glycolytic activity. Not all
cells would necessarily exhibit all of the processes shown in the upper right
quadrant. La− can be formed throughout the cytosol; two particular locations
are noted for which there is evidence of compartmentation with glycolysis,
one in association with the Na+-K+-ATPase pump in the sarcolemma and the
other for skeletal and cardiac muscle, the Ca2+-ATPase in the sarcoplasmic
reticulum membrane. The sarcolemma is illustrated by the thick double lines
at the top of the cartoon whereas the inner and outer mitochondrial
membranes are dramatically enlarged to demonstrate possible La−
pathways. The gaps in the outer mitochondrial membrane illustrate that it is
freely permeable to most small molecules (but probably not permeable to
LDH). La− is shown in bold and red, and larger than pyruvate (Pyr−) to
indicate that La− is typically present in much higher concentration than Pyr−
(i.e., a high La−/Pyr− ratio). Whether La− is converted back to Pyr− outside
the intermembrane space, inside the space, or via a mitochondrial LDH, the
resulting NADH + H+ would be shuttled across the inner mitochondrial
membrane via the malate-aspartate and glycerol phosphate shuttles. Pyr−
could be transported across the inner mitochondrial membrane by either a
mitochondrial pyruvate carrier (MPC) or a monocarboxylate transporter (MCT),
both of which have been identified in the inner membrane. COX indicates
cytochrome oxidase; cLDH, cytosolic lactate dehydrogenase; CD147,
single-span transmembrane glycoprotein; ETC II and III, electron transport
chain complexes II and III; Gly, glycogen; Glu, glucose; imLDH, LDH in the
intermembrane space; Inner, inner mitochondrial membrane; La−, lactate;
MCT1, monocarboxylate transporter 1; mLDH, mitochondrial LDH; MPC,
mitochondrial pyruvate carrier; NADH-dh, NADH dehydrogenase complex I;
Outer, outer mitochondrial membrane; Pyr−, pyruvate. Conceived from (1)
Stainsby and Brooks (1990), (2) Hashimoto et al. (2006), and (3) Gladden
(2008).
most likely to the intermembrane space where LDH is attached to
the outer side of the inner mitochondrial membrane (Hashimoto
et al., 2006; Gladden, 2008). Here, La− is converted to pyru-
vate for entry into the mitochondria, given the relative “sink” for
pyruvate. Simultaneously, NADH is regenerated from the rever-
sal of the LDH reaction and its pair of electrons is shuttled across
the inner mitochondrial membrane by the malate-aspartate and
glycerol phosphate shuttles. An important difference from the
Phosphocreatine Shuttle is that two key components, La− and
pyruvate, unlike phosphocreatine, can cross the plasma mem-
brane and leave the cell.
The Cytosol-to-Mitochondria paradigm posits that La− is
always formed during glycolysis, even if La− is not accumulat-
ing and [La−] is stable. Of course, if O2 is so low that oxidative
phosphorylation is inhibited, then La− production will exceed
the rate at which oxidative metabolism can use pyruvate and
NADH, causing [La−] and La− efflux to rise. Also, if glycolytic
activity increases even with ample O2 levels, as in skeletal muscle
contracting at a moderate intensity or perhaps in activated astro-
cytes (Pellerin and Magistretti, 2011), La− production will not be
matched by pyruvate oxidation and [La−] will rise as will trans-
port of La− out of the cell. Similarly, if glycolytic enzyme activity
is enhanced and/or mitochondrial function (oxidative enzyme
activity) is downregulated such that glycolysis is favored over
oxidation, there will be an ongoing mismatch between La− pro-
duction and subsequent pyruvate and NADH oxidation resulting
in elevated [La−] and La− efflux. This latter situation is observed
in “Warburg” cancer cells (Semenza, 2008) and in COPD patients
during whole body exercise in vivo (Maltais et al., 1996).
With endurance exercise training, skeletal muscle mitochon-
drial content is increased (Holloszy and Coyle, 1984), and there
is now a larger sink for pyruvate. Increased mitochondrial oxida-
tive activity requires lower levels of stimulators (e.g., ADP) for
a particular oxidative phosphorylation rate; these same stimuli
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are allosteric stimulators of key glycolytic enzymes so glycolysis
is reduced. Additionally, if La− membrane transport is inhib-
ited, particularly in cells that already have a mismatch in which
glycolysis is favored over oxidative metabolism, it is likely that cel-
lular [La−] will rise with potentially deleterious effects on the cell
(Le Floch et al., 2011). Further, strong inhibition of total LDH
activity in glycolytic cells should prevent equilibrium and thereby
reduce La− production, accumulation, and efflux (Fantin et al.,
2006). However, the effect of changing the LDH isozyme pattern
independent of inhibition or reduction of total LDH activity is
still yet to be fully resolved (Downer et al., 2006).
FUTURE DIRECTIONS: INFLUENCE OF LDH ISOFORM AND
APPLICATIONS TO TUMOR METABOLISM
What impact does LDH isoform have and how might this
knowledge be applied to the treatment of diseases with altered
metabolism, like cancers?
First, LDH is a tetrameric enzyme composed of two protein
subunits which total approximately 135 kDa (Cahn et al., 1962).
The tetramer can assemble as five separate isozymes by forming
all combinations of theM (muscle) form (product of the Ldh-A
gene) or the H (heart) form (product of the Ldh-B gene) pro-
ducing: M4 (= A4 = LDH5), M3H1 (= A3B1 = LDH4), M2H2
(= A2B2 = LDH3), M1H3 (= A1B3 = LDH2), and H4 (= B4 =
LDH1). Results from investigations in vitro indicate differing
kinetic properties with respect to substrate affinity and inhibition
among these isozymes. The M-dominated isozymes have 3.5–7
times higher Km-values for pyruvate and La− than the H-
dominated forms. Further, the H4 types are inhibited by pyruvate
at concentrations above ∼0.2mM while the M4 types are little
affected by pyruvate concentrations as high as 5mM (Plagemann
et al., 1960; Stambaugh and Post, 1966; Quistorff and Grunnet,
2011b). The H4 isozyme is inhibited by [La−] above 20–40mM
while the M4 isozyme is less inhibited by high [La−] (Stambaugh
and Post, 1966). These points have been offered as evidence for
functional differences in cellular metabolism of various tissues
with the heart forms promoting oxidation while the muscle forms
facilitate formation of La− (Cahn et al., 1962). The LDH isozyme
distribution found in nature fits with these characteristics deter-
mined in vitro. For example, fast-twitch, glycolytic, type II skeletal
muscle fibers have a greater proportion of M-type LDH isozyme
whereas slow-twitch, oxidative, type I skeletal muscles as well
as cardiac muscle have a greater proportion of the H-type LDH
isozyme (Van Hall, 2000). Congruently, endurance exercise train-
ing decreases the proportion of the M-type LDH isozyme in the
trained muscles (Van Hall, 2000). In the brain, astrocytes (which
are postulated to have a higher glycolytic metabolism), have a
greater proportion of the M-type LDH isozyme, whereas neurons
(which are asserted to have a higher oxidative metabolism), have
a greater proportion of the H-type LDH isozyme (Schurr, 2006;
Pellerin and Magistretti, 2011). In tumors, glycolytic “Warburg-
type” cells have a greater proportion of M-type LDH isozyme
while more oxidative cancer cells have a greater proportion of
H-type LDH isozyme (Semenza, 2008). So, the circumstantial
evidence of LDH isozyme distribution patterns coincides with
the perceived function of the LDH isozymes as determined
in vitro.
The evidence cited above has led to the conclusion that
LDH isozyme pattern is a causative factor in La− metabolism.
To further elucidate the role of LDH isozyme apportionment
as a coordinator of La− metabolism, Summermatter et al.
(2013) undertook an investigation to test the role of peroxisome
proliferator-activated receptor-γ coactivator 1α (PGC-1α) as a
regulator of LDH isozyme subtype expression. PGC-1α is known
to be important in the coordination of cellular energymetabolism
(Wu et al., 1999). In response to a variety of stimuli, PGC-1α stim-
ulates mitochondrial biogenesis, promotes transition of skeletal
muscle to a more oxidative phenotype, and contributes to altered
carbohydrate and lipid metabolism (Liang and Ward, 2006).
Summermatter et al. (2013) studied muscle-specific PGC-1α
transgenic mice as well as muscle-specific PGC-1α knockout mice
and found (1) lower blood [La−] in the transgenic animals,
and higher blood [La−] in the knockout animals in response
to endurance exercise, and (2) reduced expression of M-type
LDH in the transgenic animals and reduced H-type LDH in the
knockout animals. These authors concluded, as their title asserts,
that “skeletal muscle PGC-1 α controls whole-body La− home-
ostasis through estrogen-related receptor α-dependent activation
of LDH B and repression of LDH A.” In their view, the LDH
isozyme pattern is a major player in whole body metabolism
of La−.
However, there are under-appreciated admonitions regarding
LDH isozyme functions and their potential roles in metabolism.
First, the aforementioned kinetic properties for LDH isoforms
were determined in vitro at 20 or 25◦C, and the Km-values
for pyruvate increase with temperature, approximately doubling
at 37◦C compared to 25◦C (Latner et al., 1966; Quistorff and
Grunnet, 2011b). Previously, Newsholme and Leech (1983), Van
Hall (2000), Newsholme (2004), Gladden (2008), and Quistorff
and Grunnet (2011a), have raised significant questions about the
role of LDH isozyme profiles in La− production vs. utilization,
noting that: (1) enzymes do not change the equilibrium constant
of a reaction; (2) the LDH reaction is near equilibrium, mini-
mizing allosteric effects; (3) differences in LDH isozyme function
in vivo are possibly quite small because of the higher physiological
temperatures and binding to structures or other proteins; (4) the
concentrations of La− and pyruvate needed for LDH inhibition
in vitro are much higher than the highest concentrations observed
in vivo; and (5) LDH inhibition in vitro may be due to traces of
the enol form of pyruvate that are less likely to be present in vivo.
Although Summermatter et al. (2013) state with conviction
that LDH isoform pattern is a major factor in whole body
La− metabolism, there is a fatal flaw in their design. They
ignored the fact that PGC-1 α transgenic mice have increased
mitochondrial proliferation and oxidative phosphorylation
enzymes, whereas PGC-1α knockout mice have significant reduc-
tions in cytochrome oxidase and citrate synthase activities (Arany
et al., 2005). In our opinion, these changes in mitochondrial
function, the previously noted high total LDH activity irrespec-
tive of isozyme pattern, and the near equilibrium nature of this
reaction render the conclusions of Summermatter et al. (2013)
untenable. Therefore, we conclude that the exact physiological
and biochemical roles of LDH isozymes in vivo remain to be
definitively elucidated.
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Finally, with regard to tumor metabolism, understanding that
La− is the end product of glycolysis is paramount to designing
interventions for targeting cancers. Briefly, experiments by Cori
and Cori (1925) and by Warburg et al. (1927) showed that
tumors appeared to be avidly consuming glucose and produc-
ing La−. Subsequent dogma in tumor metabolism has held that
tumors exhibit a “Warburg Effect,” producing and exporting La−.
However, we now know that not only do different tumor types
handle La− differently (some are net producers; some are net con-
sumers), but even within a single tumor there may be shuttling
between different cell types; a cell to cell La− shuttle (Semenza,
2008). Many cancer cells are poor consumers of lactate (Sonveaux
et al., 2008) sparking speculation that a La−-protected hypo-
glycemia may be therapeutic (Nijsten and van Dam, 2009). In
contrast, some tumors avidly use La− as a fuel, and respond
to supplemental La− with increased proliferation and vascular-
ity, likely a direct result of upregulation of vascular endothelial
growth factor (VEGF) and hypoxia-inducible factor 1α (HIF-1α).
In a recent study on an animal model of a sarcoma, Goodwin et al.
(2014) reported that La− drove sarcomagenesis in the absence
of hypoxia. Amazingly, our understanding of La− metabolism
in cancer remains unsettled almost 90 years after Warburg’s first
studies.
CONCLUSIONS
Our understanding of La− formation has changed drastically
since its discovery. Traditionally, pyruvate has been thought to
be the end product of glycolysis when O2 is present and La−
the end product during periods of dysoxia. In the late twenti-
eth century and early twenty-first century it was discovered that
O2 is not limiting to oxidative phosphorylation under most cel-
lular conditions, and La− is indeed produced even when there
is no limitation on the rate of O2 delivery to mitochondria.
Further reflection on the activity of the LDH enzyme and the
equilibrium constant of its reaction advance the proposition that
La− is the primary end product of glycolysis under most, if not
all metabolic conditions in most cells. The role of the differ-
ent LDH isozymes in metabolism is not as clearly evident as
most researchers suggest, and we conclude that their exact func-
tion remains undiscovered. Whether or not we are correct about
the Cytosol-to-Mitochondria Lactate Shuttle as described here
and the uncertain role of the LDH isoforms will be difficult
to evaluate under conditions in vivo. One approach is model-
ing in silico. Understanding the exact mechanisms of glycolysis
and La− metabolism will not only deepen our understanding of
metabolism in healthy tissues, but will also lend insight into dis-
eased or injured tissues, with the most obvious applications being
the deranged carbohydrate metabolism present in cancer cells
(Vander Heiden et al., 2009) and cerebral metabolism following
traumatic brain injury (Brooks and Martin, 2014).
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